Alyeska Investment Group’s Orchestra BioMed OBIO Stock Holding History

Alyeska Investment Group’s Portfolio OBIO Stock Details OBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.32M	Hold	1,000,000	–	–	0.01%	518
2026 Q1	$4.25M	Hold	1,000,000	–	–	0.01%	490
2025 Q4	$4.15M	Sell	1,000,000 -365,482	-27%	-$1.47M	0.01%	476
2025 Q3	$3.39M	Buy	+1,365,482	New	+$3.77M	0.01%	480
2022 Q3	–	Sell	-25,000	Closed	-$249K	–	451
2022 Q2	$249K	Hold	25,000	–	–	﹤0.01%	544
2022 Q1	$248K	Hold	25,000	–	–	﹤0.01%	563
2021 Q4	$252K	Hold	25,000	–	–	﹤0.01%	582
2021 Q3	$247K	Hold	25,000	–	–	﹤0.01%	655
2021 Q2	$255K	Hold	25,000	–	–	﹤0.01%	678
2021 Q1	$280K	Hold	25,000	–	–	﹤0.01%	698
2020 Q4	$320K	Sell	25,000 -200	-0.8%	-$2.28K	﹤0.01%	468
2020 Q3	$277K	Buy	+25,200	New	+$283K	﹤0.01%	438

Other funds holding OBIO

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PBM

Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Alyeska Investment Group's OBIO Position: Q2 2026 in Review

Alyeska Investment Group held its Orchestra BioMed (OBIO) position steady in Q2 2026 at 1,000,000 shares worth $4.32M. The position accounts for 0.01% of the portfolio, ranked #518.

Alyeska Investment Group first reported a position in OBIO in Q3 2020 and has held it in 12 quarters since. 77 funds tracked by Wall St. Rank hold OBIO as of Q2 2026.

Alyeska Investment Group held 1,000,000 shares of Orchestra BioMed worth $4.32M as of Q2 2026.
Alyeska Investment Group left its Orchestra BioMed share count unchanged in Q2 2026.
Orchestra BioMed made up 0.01% of Alyeska Investment Group's portfolio in Q2 2026, its #518 holding.
Alyeska Investment Group first reported a position in Orchestra BioMed in Q3 2020 and has held it in 12 quarters since.
77 funds tracked by Wall St. Rank held Orchestra BioMed as of Q2 2026.

Based on Alyeska Investment Group's 13F filing for Q2 2026, filed 14 Aug 2026.